Video interview with David Budd18 Apr 2016 16:56
http://tinyurl.com/z9crjeq
David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says the news it has reached a major milestone in its development with the full commercial launch of its Genedrive tuberculosis (TB) and antibiotic resistance test, is “hugely significant”.
The company, a specialist in molecular diagnostics and personalised medicine, has teamed up with Xcelris Labs to start selling the product in India.
Next up, Budd says, the company hopes to build up a “menu of tests” over time, now that the company has a “robust technology platform in place”.